Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xolair to Improve Tolerability of Allergen Immunotherapy in Moderate Persistent Allergic Asthma
NCT00691873Phase 4Completed
- Sponsor
- University of Mississippi Medical Center
- Start
- May 2006
- Primary completion
- May 2007
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of omalizumab in allergic asthma, sponsored by University of Mississippi Medical Center. Primary endpoint: Systemic allergic reactions to specific immunotherapy at 26 weeks. Started May 2006; status: completed.
02
Drugs
omalizumab
03
Conditions
allergic asthma
Beyond the preview
Go deeper on NCT00691873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00691873.